| Literature DB >> 35130081 |
Julia O'Mahony1, Brenda Banwell2, Audrey Laporte3, Adalsteinn Brown4, Lady Bolongaita3, Amit Bar-Or5, E Ann Yeh6, Ruth Ann Marrie7.
Abstract
BACKGROUND: We previously found that children with the chronic disease multiple sclerosis (MS) reported lower health-related quality of life (HRQoL) when compared to children who experienced the transient illness termed monophasic acquired demyelinating syndromes (monoADS). Parents of children with MS also reported lower HRQoL.Entities:
Keywords: CIS; Demyelination; multiple sclerosis; outcome measurement; quality of life
Mesh:
Year: 2022 PMID: 35130081 PMCID: PMC9189724 DOI: 10.1177/13524585211061521
Source DB: PubMed Journal: Mult Scler ISSN: 1352-4585 Impact factor: 5.855
Figure 1.Conception of hypothesized mediation of the child’s HRQoL by the parents’ HRQoL. We hypothesized that the HRQoL of parents would mediate the relationship between the child’s diagnosis of MS and the child’s HRQoL. We expected to observe an association between that diagnosis of MS and the child’s HRQoL (effect of diagnosis on child’s HRQoL represented by c’). The effect between the diagnosis and the mediator (parent’s HRQoL) is represented by a. The effect between the mediator and the child’s HRQoL is represented by b. We hypothesized that some covariates would associates with both the child’s diagnosis and the child’s HRQoL while other covariates would associate with only the child’s diagnosis.
Figure 2.Participants enrolled with pediatric-onset multiple sclerosis (MS) and monophasic acquired demyelinating syndromes (monoADS). Between September 2004 and January 2018, 443 children were enrolled, of whom 309 were eligible for the present analysis. Of these, 44 declined to complete the HRQoL questionnaires leaving 265 families who completed at least one of the three questionnaires (Child Inventory, Parent HRQoL, and Family HRQoL). Of the 234 families who completed contemporaneously matched triads of questionnaires, 207 also completed the BSMSS Occupation Scale and were included in these analysis. Among the 207 unique families included in this analysis, 1,863 questionnaires from 621 time points were included. Ten participants submitted incomplete questionnaires (2 Child Inventories and 8 Family Impact Modules) and were therefore excluded from the current analyses. These participants are categorized in Figure 2 as not having completed the questionnaires.2 31 unique families were not included in this analysis because they did not complete the Child Inventory, Parent HRQoL, and Family HRQoL (triad) at a single time point. These 31 unique families did however complete 51 questionnaires at 42 unique time points.3 27 unique families were not included in these analyses because they did not complete the BSMSS Occupation Scale. These 27 unique families did however complete 175 questionnaires at 67 unique time points (triads were completed at 48 of the 67 time points). Twelve of these participants also submitted incomplete Family Impact Modules at a single time point; the incomplete Family Impact Modules and the completed Child Inventories were disregarded at those time points.4 Among the 207 unique families included in these analyses, 151 questionnaires from 110 unique time points were excluded from this analysis because they were not contemporaneously matched within a triad (Child Inventory, Parent HRQoL and Family HRQoL). Two participants submitted incomplete Child Inventory Modules and were therefore excluded and categorized as having not completed the questionnaires. Participants included in this analysis (n = 207) did not differ (p > 0.05) from those who were eligible to complete the questionnaire and were excluded (n = 102) from this analysis (either because the participant declined to complete or did not complete a contemporaneously matched triad and BSMSS) in terms of MS diagnosis, age at onset, and sex. Participants who were included in the current analyses had a longer length of follow-up (median (IQR) 7.24 (5.18–9.05) years) than those who were not included (5.46 (3.09–7.45) years; p < 0.0001).
Characteristics of the cohort.
| Characteristic | monoADS ( | MS ( |
|
|---|---|---|---|
| Characteristics at neurological onset | |||
| Female, | 64 (45) | 43 (66) |
|
| Age at neurological onset (years), median (IQR), min—max | 8.67 (4.62–12.34) | 14.49 (11.75–15.72) |
|
| Length of stay for first attack (days), median (IQR) | 7 (5–11) | 3 (0–7) |
|
| Participant born in Canada, | 130 (92) | 52 (80) |
|
|
| 27.5 (17.5–35) | 25 (12.5–35) | 0.34 |
| Number of children in the family, median (IQR) | 2 (2–3) | 2 (2–3) | 0.74 |
| Characteristics at first HRQoL assessment | |||
| Age at questionnaire (years), median (IQR), min—max | 12.99 (8.86–16.34) | 17.19 (14.85–19.52) |
|
|
| 13 (9) | 3 (5) | 0.05 |
|
| 3 (2) | 11 (17) | 0.06 |
| Disease duration (years), median (IQR) | 4.15 (3.02–6.09) | 3.13 (0.46–6.05) |
|
|
| 25 (18) | 14 (22) | 0.56 |
|
| 57 (40) | 33 (51) | 0.62 |
|
| 15 (11) | 8 (12) | 0.93 |
|
| |||
| Child’s age at questionnaire (years), median (IQR) | 14.40 (11.08–6.15) | 17.87 (16.25–20.24) |
|
| Functional neurological impairments, median (IQR) | 0 (0–0) | 0 (0–0) | 0.06 |
| Disease duration (years), median (IQR) | 5.69 (4.01–7.38) | 4.73 (1.02–7.16) |
|
| PedsQLTM HRQoL results | |||
| Number of questionnaires per participant, median (IQR) | 3 (2–4) | 2 (2–4) | 0.77 |
| g,hHealth-related quality of life of the child
( | 86.25 (77.17–92.66) | 79.12 (65.22–89.86) |
|
|
| 89.58 (78.58–97.29) | 78.13 (62.92–92.12) |
|
|
| 92.19 (79.69–97.27) | 73.83 (55.47–85.94) |
|
monoADS: monophasic acquired demyelinating syndromes; MS: multiple sclerosis; IQR: interquartile range; BSMSS: Barratt Simplified Measure of Social Status; HRQoL: health-related quality of life. P values < 0.05 were considered statistically significant and presented in bold text.
Parental BSMSS Occupation Score is ordinal and varies from 5 (lowest level of occupation) to 45 (highest level of occupation).
Among the 65 MS participants, three (5%) experienced persistent neurological impairments without recovery; one child experienced ambulatory impairments, but did not require mobility aid, and two experienced permanent uniocular visual loss. Eleven (17%) children with MS were experienced residual neurological impairments following relapses that occurred greater than 30 days prior to HRQoL observation that subsequently resolved (two sensory, two ambulatory who did not require mobility aid, four ambulatory who required mobility aid, one visual, and one pyramidal) and one child experienced two discrete transient episodes of visual and pyramidal dysfunction. Among the 142 monoADS participants, 13 experienced persistent neurological impairments without recovery following their sole episode of demyelination, including three children with bowel or bladder dysfunction, one child with ambulatory impairments who is wheelchair dependent, two children with ambulatory impairments who required mobility aid, one child with ambulatory impairments who did not require mobility aid, one child with pyramidal dysfunction, one child with sensory dysfunction, one child with moderate upper limb hemiparesis, and three children with visual impairments.
25 unique participants with monoADS and 14 unique participants with MS reported one or more comorbidities.
57 unique sets of parents of children with monoADS and 33 unique sets of parents of children with MS reported one or more health conditions.
15 unique families of children with monoADS and 8 unique families of children with MS reported one or more sibling with at least one health condition.
Average per participant over period of observation (between first HRQoL assessment to most recent HRQoL assessment).
PedsQLTM Questionnaire scores are continuous from 0 (worst health) to 100 (best health).
The mean (SD) HRQoL of children with MS aged 8 to 18 was 79.68 (15.06) and was 82.25 (13.34) for children with monoADS. Notably, these values fall within one SD of the mean of a large school-aged population of healthy children (n = 3,990; mean (SD) 81.08 (13.07)) and those experiencing chronic illness (n = 201; mean (SD) 71.59 (16.17)) within the same age range.
Comorbidities and health conditions of participant families.
| Condition | Number of affected family members | |||||
|---|---|---|---|---|---|---|
| Participants |
|
|
| |||
|
|
| Combined MS and monoADS | ||||
| Bipolar disorder | 3 | 0 | 3 | 4 | 2 | 2 |
| Anxiety disorder | 3 | 7 | 10 | 1 | 2 | 1 |
| Depression | 0 | 6 | 6 | 3 | 7 | 2 |
| Hyperlipidemia | 0 | 0 | 0 | 0 | 2 | 4 |
| Hypertension | 0 | 0 | 0 | 1 | 4 | 7 |
| Heart trouble | 0 | 0 | 0 | 0 | 0 | 3 |
| Diabetes mellitus | 0 | 0 | 0 | 1 | 6 | 13 |
| Cancers | 0 | 2 | 2 | 1 | 7 | 5 |
| Glaucoma | 0 | 0 | 0 | 0 | 1 | 0 |
| Thyroid disease | 2 | 3 | 5 | 2 | 19 | 3 |
| Lupus | 0 | 0 | 0 | 0 | 4 | 1 |
| Inflammatory bowel disease (IBD) | 0 | 1 | 1 | 1 | 6 | 1 |
| Irritable bowel syndrome (IBS) | 0 | 3 | 3 | 0 | 0 | 1 |
| Epilepsy | 2 | 3 | 5 | 2 | 2 | 1 |
| Migraine | 2 | 4 | 6 | 2 | 2 | 1 |
| Rheumatoid arthritis | 1 | 0 | 1 | 0 | 5 | 0 |
| Blood disease | 0 | 0 | 0 | 1 | 1 | 1 |
| Kidney disease | 0 | 1 | 1 | 0 | 2 | 1 |
| Lung trouble | 0 | 0 | 0 | 0 | 1 | 0 |
| Open ulcer of the stomach | 0 | 0 | 0 | 0 | 1 | 0 |
| Osteoporosis | 0 | 0 | 0 | 0 | 1 | 0 |
| Guillain–Barré Syndrome (GBS) | 1 | 0 | 1 | 0 | 0 | 1 |
| Tics | 1 | 2 | 3 | 0 | 0 | 0 |
| Endocrine disorder | 1 | 1 | 2 | 0 | 0 | 0 |
| Parkinson’s disease | 0 | 0 | 0 | 0 | 0 | 1 |
| Central nervous system (CNS) aneurysm | 0 | 0 | 0 | 0 | 0 | 1 |
| Autism spectrum disorder (ASD) | 0 | 0 | 0 | 4 | 0 | 0 |
| Multiple sclerosis (MS) | 0 | 0 | 0 | 2 | 2 | 1 |
| Myasthenia gravis (MG) | 0 | 0 | 0 | 0 | 1 | 0 |
| Sarcoidosis | 0 | 0 | 0 | 0 | 0 | 1 |
| Usher’s syndrome | 0 | 1 | 1 | 1 | 0 | 0 |
| Total | 16 | 34 | 50 | 26 | 78 | 52 |
monoADS: monophasic acquired demyelinating syndromes; MS: multiple sclerosis; IBD: inflammatory bowel disease; IBS: Irritable bowel syndrome; GBS: Guillain-Barré syndrome; CNS: Central nervous system; ASD: Autism spectrum disorder; MG: Myasthenia gravis.
15 unique families of children with monoADS reported 14 comorbidities among siblings of the participant; 13 reported one comorbidity; two families reported two comorbidities. Eight unique families of children with MS reported health conditions among siblings of the participant; seven reported one health condition and one reported two health conditions.
57 unique sets of parents of children with monoADS reported health conditions; 43 reported one health condition, eight reported two health conditions, two reported three health conditions and three reported four health conditions; one reported five health conditions. 33 unique sets of parents of children with MS reported health conditions; 23 reported one health condition, seven reported two health conditions, one reported three health conditions and two reported four health conditions.
14 unique participants with MS reported one or more comorbidities; 12 participants each reported a single comorbidity; two participants reported two comorbidities.
25 unique participants with monoADS reported one or more comorbidities; 18 reported one comorbidity; five participants reported two comorbidities; two reported three comorbidities.
Bivariate analyses of associations between the child’s HRQoL and covariates.
| Predictor | Beta coefficient (95% CI) | Test statistic | |
|---|---|---|---|
| Key predictor | |||
| Parent’s HRQoL | 0.26 (0.20, 0.32) | 8.57 |
|
| Instrumental Variable | |||
| Family’s HRQoL | 0.26 (0.20, 0.32) | 8.90 |
|
| Time-invariant predictors | |||
| MS diagnosis | –6.36 (–10.26, –2.46) | –3.19 |
|
| Child’s sex | –2.58 (–6.28, 1.24) | –1.32 | 0.17 |
| Child’s age at neurological onset | –0.25 (–0.65, 0.14) | –1.25 | 0.21 |
| Length of stay for first attack | –0.003 (–0.20, 0.19) | –0.03 | 0.98 |
| Child born in Canada | –3.16 (–8.77, 2.44) | –1.11 | 0.27 |
| BSMSS Occupation Score | 0.20 (0.04, 0.36) | 2.51 |
|
| Number of children in the family | 0.14 (–1.85, 1.57) | –0.16 | 0.88 |
| Child’s comorbidities | –8.90 (–12.08, –5.72) | –5.48 |
|
| Health conditions of parents | –2.16 (–4.14, –0.19) | –2.15 |
|
| Health conditions of siblings | –1.42 (–6.34, 3.50) | –0.56 | 0.57 |
| Time-variant predictors | |||
| Child’s age at questionnaire | –0.11 (–0.40, 0.19) | –0.71 | 0.48 |
| Functional neurological impairments | –4.29 (–8.19, –0.39) | –2.15 |
|
HRQoL: health-related quality of life; CI: confidence interval; MS: multiple sclerosis; BSMSS: Barratt Simplified Measure of Social Status. P values < 0.05 were considered statistically significant and presented in bold text.
Adjusted beta coefficients (95% confidence intervals) for the associations between the listed outcomes and predictors after adjusting for covariates .
| Models | Outcome | Predictor(s) | Beta coefficient (95% CI) | ||
|---|---|---|---|---|---|
| Model 1 | Child’s HRQoL | MS Diagnosis | –6.38 (–10.72, –2.04) |
| 0.15 |
| Model 2 | Parent’s HRQoL | MS Diagnosis | –9.91 (–14.72, –5.11) |
| 0.16 |
| Model 3 | Child’s HRQoL | Parent’s HRQoL | 0.33 (0.24, 0.43) |
| 0.26 |
| Model 4 | Child’s HRQoL | Parent’s HRQoL | 0.32 (0.22, 0.41) |
| 0.27 |
| MS Diagnosis | –3.16 (–7.27, 0.95) | 0.13 |
CI: confidence interval; HRQoL: health-related quality of life; MS: multiple sclerosis. P values < 0.05 were considered statistically significant and presented in bold text.
All four models were adjusted for sex, age at onset, length of stay in hospital for first attack, born in Canada, BSMSS Occupation Score, number of siblings, comorbidities of the participant, health conditions of the participant’s parents, and health conditions of the participant’s siblings, participant’s age at the time of HRQoL assessment, and presence of functional neurological impairments.
Model 1 showed that the diagnosis of MS was associated with lower HRQoL of the child when we adjusted for covariates, but not parental HRQoL. The standardized beta coefficient for MS Diagnosis in Model 1 is the direct effect of the diagnosis on the child’s HRQoL (c’ in Figure 1). Model 2 showed an association between the diagnosis of MS and lower parental HRQoL (the mediator). The standardized beta coefficient for the MS Diagnosis in Model 2 is the partial indirect effect of the diagnosis on the child’s HRQoL (a in Figure 1). Model 3 showed that lower parental HRQoL (the mediator) was associated with lower HRQoL of the child. The standardized beta coefficient for the Parent’s HRQoL in Model 3 is the partial indirect effect of the diagnosis on the child’s HRQoL (b in Figure 1). Finally, we observed that the association shown in Model 1 between the diagnosis of MS and the child’s HRQoL diminished after adjusting for parental HRQoL (Model 4).